GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

Hansoh Pharmaceutical Group Company 3692.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

34.86

+0.17%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥17.49bn

FY2016FY2025

Net income

CN¥6.47bn

FY2016FY2025

Free cash flow

CN¥7.27bn

FY2016FY2025

Shareholders' equity

CN¥41.17bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥17.49bnCN¥12.26bnCN¥10.10bnCN¥10.92bnCN¥11.56bnCN¥8.69bnCN¥8.68bnCN¥7.72bnCN¥6.19bnCN¥5.43bn
Gross profitCN¥15.72bnCN¥11.16bnCN¥9.07bnCN¥9.91bnCN¥10.55bnCN¥7.89bnCN¥7.95bnCN¥7.12bnCN¥5.73bnCN¥5.04bn
Research and developmentCN¥3.91bnCN¥2.70bnCN¥2.10bnCN¥1.97bnCN¥2.09bnCN¥1.25bnCN¥1.12bnCN¥881.3mCN¥575.5mCN¥403.1m
Operating incomeCN¥6.30bnCN¥4.03bnCN¥2.84bnCN¥3.11bnCN¥3.90bnCN¥2.77bnCN¥2.78bnCN¥2.32bnCN¥1.93bnCN¥1.81bn
Net incomeCN¥6.47bnCN¥4.37bnCN¥3.28bnCN¥3.01bnCN¥3.16bnCN¥2.57bnCN¥2.56bnCN¥1.90bnCN¥1.60bnCN¥1.48bn
Diluted earnings per share1.080.730.540.510.530.430.440.380.280.26

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥46.45bnCN¥36.84bnCN¥38.45bnCN¥34.92bnCN¥31.61bnCN¥20.79bnCN¥19.58bnCN¥8.41bnCN¥5.87bnCN¥4.82bn
Cash and short-term investmentsCN¥36.75bnCN¥27.22bnCN¥28.93bnCN¥25.17bnCN¥22.04bnCN¥13.73bnCN¥14.59bnCN¥3.98bnCN¥2.09bnCN¥1.51bn
Total liabilitiesCN¥5.28bnCN¥3.47bnCN¥8.43bnCN¥8.56bnCN¥8.30bnCN¥2.92bnCN¥6.53bnCN¥6.77bnCN¥1.63bnCN¥2.06bn
DebtCN¥122.3mCN¥117.9mCN¥4.30bnCN¥4.38bnCN¥3.83bnCN¥92.7mCN¥9.4m———
Shareholders' equityCN¥41.17bnCN¥33.38bnCN¥30.02bnCN¥26.36bnCN¥23.31bnCN¥17.88bnCN¥13.04bnCN¥1.31bnCN¥3.90bnCN¥1.85bn
Shares outstanding6,005m5,953m6,096m5,939m6,003m5,923m5,789m5,000m5,706m5,706m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥7.84bnCN¥3.86bnCN¥3.63bnCN¥3.19bnCN¥3.00bnCN¥2.39bnCN¥3.33bnCN¥2.07bnCN¥1.40bnCN¥1.25bn
Capital spending−CN¥569.6m−CN¥222.0m−CN¥255.6m−CN¥317.5m−CN¥535.4m−CN¥1.43bn−CN¥592.5m−CN¥407.2m−CN¥263.1m−CN¥273.5m
Free cash flowCN¥7.27bnCN¥3.64bnCN¥3.37bnCN¥2.87bnCN¥2.46bnCN¥962.8mCN¥2.74bnCN¥1.67bnCN¥1.14bnCN¥973.0m
Dividends paid−CN¥2.34bn−CN¥1.86bn−CN¥758.9m−CN¥828.8m−CN¥443.2m−CN¥4.20bn−CN¥1.50bn−CN¥1.50bn−CN¥404.1m−CN¥2.37bn

Latest quarters

By quarter end

Jun 2026Dec 2025Jun 2025Dec 2024Jun 2024Dec 2023Jun 2023Dec 2022
RevenueCN¥9.53bnCN¥8.84bnCN¥8.65bnCN¥5.76bnCN¥6.51bnCN¥5.59bnCN¥5.25bnCN¥5.76bn
Gross profitCN¥8.76bnCN¥7.86bnCN¥7.86bnCN¥5.22bnCN¥5.92bnCN¥5.09bnCN¥4.63bnCN¥5.21bn
Operating incomeCN¥4.25bnCN¥2.63bnCN¥3.67bnCN¥1.30bnCN¥2.65bnCN¥1.68bnCN¥1.22bnCN¥1.60bn
Net incomeCN¥4.89bnCN¥2.82bnCN¥3.65bnCN¥1.65bnCN¥2.73bnCN¥1.99bnCN¥1.50bnCN¥1.50bn
Diluted earnings per share0.800.470.610.280.460.330.250.25
Cash from operations—CN¥4.60bnCN¥5.00bnCN¥1.18bnCN¥2.68bnCN¥2.29bnCN¥1.33bnCN¥1.13bn
Capital spending—−CN¥213.0m−CN¥216.0m−CN¥120.0m−CN¥101.0m−CN¥147.0m−CN¥107.0m−CN¥101.0m
Free cash flow—CN¥4.39bnCN¥4.79bnCN¥1.06bnCN¥2.58bnCN¥2.15bnCN¥1.23bnCN¥1.02bn
Total assetsCN¥54.23bnCN¥46.45bnCN¥40.81bnCN¥31.66bnCN¥31.67bnCN¥33.04bnCN¥37.17bnCN¥34.92bn
Cash and short-term investmentsCN¥43.50bnCN¥36.75bnCN¥31.56bnCN¥23.39bnCN¥23.50bnCN¥24.86bnCN¥27.39bnCN¥25.17bn
DebtCN¥4.77bnCN¥122.3mCN¥136.0mCN¥117.9mCN¥119.7mCN¥4.30bnCN¥5.30bnCN¥5.09bn
Shareholders' equityCN¥43.95bnCN¥41.17bnCN¥36.19bnCN¥28.68bnCN¥27.90bnCN¥25.79bnCN¥28.13bnCN¥26.36bn

Financial ratios

Data as of 5 Sept 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Gross margin89.9%91.0%89.8%90.7%91.2%90.8%
Operating margin36.0%32.9%28.1%28.5%33.7%31.9%
Net margin37.0%35.7%32.4%27.5%27.3%29.6%
Return on equity15.7%15.2%12.7%11.4%13.5%14.4%
Return on assets13.9%13.8%9.9%8.6%10.0%12.4%
Free cash flow yield3.3%1.9%1.5%1.4%1.4%1.8%
Revenue growth22.6%21.3%7.7%-5.6%14.3%0.1%
Earnings growth27.1%33.4%26.9%-4.8%5.6%0.5%
Current ratio8.09x10.18x4.21x9.86x7.67x6.43x
Debt to equity0.00x0.00x0.16x0.19x0.19x0.00x
Equity ratio88.6%90.6%78.1%75.5%73.7%86.0%
Interest coverage1712.71x602.65x42.58x45.94x63.48x1685.66x
R&D as a share of sales22.3%22.0%20.8%18.0%18.1%14.4%
Buybacks as a share of market value-0.9%2.3%-2.6%1.1%-1.4%-2.3%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue17.0%15.0%—
Operating income26.6%17.8%—
Net income29.1%20.3%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin90.3%90.3%90.5%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019
Price to earnings29.620.825.925.931.976.651.8
Price to sales10.97.48.47.18.722.615.3

Dividends and splits

Per share, in the currency the company pays

Paid for 5 years. Last went ex-dividend on 3 Jul 2026.

FY2026FY2025FY2024FY2023FY2022FY2021
Paid in the year0.200.3670.3730.1210.230.077

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.